Effects of monoamine oxidase a inhibition on plasma biogenic amine metabolites in depressed patients

The main metabolites of nonadrenalin, dopamine, and serotonin—3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), respectively—were estimated in plasma of 21 depressed patients before and after 2 and 4 weeks of treatment with the monamine oxidase...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 1994-06, Vol.52 (3), p.259-264
Main Authors: Markianos, Manolis, Alevizos, Basil, Hatzimanolis, John, Stefanis, Costas
Format: Article
Language:English
Subjects:
3-methoxy-4-hydroxyphenylglycol
5-hydroxyindoleacetic acid
Adult
Affective disorder
Arousal - physiology
Benzamides - adverse effects
Benzamides - therapeutic use
Biogenic Amines - blood
Biological and medical sciences
Bipolar Disorder - blood
Bipolar Disorder - drug therapy
Chromatography, High Pressure Liquid
Depressive Disorder - blood
Depressive Disorder - drug therapy
Dopamine - blood
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
homovanillic acid
Homovanillic Acid - blood
Humans
Hydroxyindoleacetic Acid - blood
Male
Medical sciences
Methoxyhydroxyphenylglycol - blood
Middle Aged
Moclobemide
Monoamine Oxidase Inhibitors - adverse effects
Monoamine Oxidase Inhibitors - therapeutic use
Neuropharmacology
Norepinephrine - blood
Personality Inventory
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Serotonin - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The main metabolites of nonadrenalin, dopamine, and serotonin—3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), respectively—were estimated in plasma of 21 depressed patients before and after 2 and 4 weeks of treatment with the monamine oxidase-type A (MAO-A) inhibitor moclobemide (mean final daily dose = 8.9 mg/kg body weight). The treatment caused significant mean reductions in plasma MHPG and HVA (46% and 30%, respectively), while plasma 5-HIAA was unchanged. Multiple regression analysis revealed associations between reductions in MHPG and changes on the anxiety-somatization factor of the Hamilton Rating Scale for Depression (HRSD), and between reductions in HVA and changes in the HRSD factors cognitive disturbance and retardation.
ISSN:0165-1781
1872-7123
DOI:10.1016/0165-1781(94)90071-X